Devine, Progen split
06 November, 2002 by Pete YoungQueensland biotech Progen Industries and business development vice president Dr Peter Devine have parted company.
Abbott-Domantis agreement may affect Peptech's future
06 November, 2002 by Graeme O'NeillPharmaceutical giant Abbott Laboratories has signed an agreement with UK-based Domantis that gives it non-exclusive access to Domantis' single-domain designer technology for new 'lite' antibody therapeutics.
Bioprocessing feature: Out of the vat
06 November, 2002 by Melissa TrudingerBioprocessing and fermentation are essential parts of the biotechnology product development cycle. If a drug or therapeutic is produced by a living organism, whether it's bacteria, yeast, plant cells or mammalian cells, some form of large-scale fermentation or culture is required to produce the entity, and usually some form of downstream processing is necessary to extract, purify, concentrate and formulate the end product.
VRI receives TGA approval
04 November, 2002 by Melissa TrudingerWestern Australian probiotics company VRI BioMedical has received Therapeutic Goods Administration (TGA) approval for its gastrointestinal product, Progastrim.
Ventracor to sell off its former core division
04 November, 2002 by Melissa TrudingerVentracor is in negotiations to sell off its e-Health division to a potential purchaser identified after a worldwide search.
GSK research award goes to epilepsy pioneer
01 November, 2002 by Melissa TrudingerAustralian epilepsy researcher Prof Sam Berkovic has been awarded the 2002 GlaxoSmithKline (GSK) Australia Award for Research Excellence for his pioneering discoveries of the genetic causes of epilepsy.
Cerylid, Peter Mac collaborate on anti-cancer drugs
31 October, 2002 by Melissa TrudingerCerylid and the Peter MacCallum Cancer Institute have set up a collaboration to look for new anti-cancer drug leads, using Cerylid's natural products library as a source.
Peptech down as European royalties cease
30 October, 2002 by Melissa TrudingerPeptech's share price plunged more than 50 per cent today after announcing that it had ceased receiving European royalties from US-based Centocor.
Meditech on course for Phase II after capital raising
29 October, 2002 by Graeme O'NeillMelbourne biotech company Meditech Research has launched a $3.5 million capital raising, underwritten by Intersuisse, to fund initial Phase II clinical trials of its HyACT anti-cancer treatments.
Starpharma subsidiary awarded $3.5 million by US govt
29 October, 2002 by Melissa TrudingerDendritic Nanotechnologies (DNT), a subsidiary of Melbourne organisation Starpharma, has received $US3.5 million ($6.3 million) from the United States government to establish facilities for applied dendrimer research and development at Central Michigan University (CMU).
Greenpeace dust claims 'a cheap shot': GM expert
28 October, 2002 by Graeme O'NeillAn expert on genetically modified crops has dismissed claims by Greenpeace that last week's massive dust storm over eastern Australia disproved claims that GE canola pollen would not travel very far.
Nuts ain't nuts: fine-tuning the macadamia industry
25 October, 2002 by Graeme O'NeillIn 1881 an American, William Purvis, pocketed a handful of macadamia nuts from a tree in the Gold Coast hinterland and spirited them away to Hawaii.
ResMed picks up exporter gong
25 October, 2002 by Melissa TrudingerAustralian sleep apnoea devices manufacturer ResMed has taken out the 2002 NSW Premier's Exporter of the Year Award as well as the award for the 2002 NSW Exporter of the Year in the Large Advanced Manufacturer category, which is for manufacturers with more than $20 million in annual sales.
Silver lining for Sunshine Heart
25 October, 2002 by Graeme O'NeillA new Australian developed device that boosts failing hearts while they repair themselves has won a silver medal in the Far Eastern Economic Review's annual Asian Innovation Awards.
How science can help get farmers through the big dry
24 October, 2002 by Melissa TrudingerOne of Australia's recurring agricultural problems is drought, and this year is no exception, with widespread drought conditions across many of Australia's prime agricultural regions. So it's not surprising to discover that developing drought-tolerant crops is a major target for breeders and agricultural biotechnologists around Australia.
